Ocean Biomedical
Yahoo Finance • 8 months ago
13 Hot Stocks to Invest in According to Wall Street Analysts
In this piece, we will take a look at the 13 hot stocks to invest in according to Wall Street analysts. If you want to skip our overview of the stock market and the latest news, then you can skip ahead to the 5 Hot Stocks to Invest in Acco... Full story
Yahoo Finance • 12 months ago
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
PROVIDENCE, Rhode Island, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on November 22, 2023, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Compa... Full story
Yahoo Finance • last year
Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics
Providence, Rhode Island, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ:OCEA), a biopharmaceutical company working to accelerate the development of compelling discoveries from top research scientists, today announced t... Full story
Yahoo Finance • last year
Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register Now
MIAMI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 64th Emerging Growth Conference on November 1st and 2nd, 2023. The Emerging Growth Conference identif... Full story
Yahoo Finance • last year
Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus Infection
Providence, RI, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ:OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today announced that its joint vent... Full story
Yahoo Finance • last year
Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan Kurtis
Providence, RI, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ:OCEA), today announced that its Chief Scientist, Jonathan Kurtis MD, PhD has received the prestigious Falk Medical Research Trust Transformational Award to... Full story
Yahoo Finance • last year
Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics
Providence, Rhode Island, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ:OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today announced that its... Full story
Yahoo Finance • last year
Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide
Providence, Rhode Island, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ:OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, and Virion Therapeutics,... Full story
Yahoo Finance • last year
Updated: Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with Polar Multi-Strategy Master Fund
Providence, RI, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announces that the company and Polar Multi-Strategy Master Fund (Polar) entered into a Side Letter related to the Forward Purchase Agreement entered... Full story
Yahoo Finance • last year
Ocean Biomedical Announces Loan Commitment from Largest Stockholder; Up to $10 Million
Providence, RI, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that it has entered into a non-binding term sheet with its largest stockholder, Poseidon Bio, LLC, majority owned by Dr. Chirinjeev K... Full story
Yahoo Finance • last year
Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with a Key Financing Partner
Providence, RI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that the company and Polar Multi-Strategy Master Fund (Polar), a significant long-time financing partner of Ocean Biomedical, agreed... Full story
Yahoo Finance • last year
Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers
Company toHost Cancer R&D Update on October 19, 2023 to Share Latest Details of Multipronged Cancer Program Based on Pioneering Anti-CHI3L1 Discoveries Providence, RI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OC... Full story
Yahoo Finance • last year
Ocean Biomedical (NASDAQ: OCEA) Will Host an R&D Update Today on Malaria, and Fibrosis Programs with Scientific Co-founders Jack A. Elias, MD, and Jonathan Kurtis, MD PhD.
Presentation will be hosted live on Ocean Biomedical’s Youtube Channel at 2:00pm ET Providence, RI, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next-generation biopharma company working to accelerate the... Full story
Yahoo Finance • last year
Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S.
Ocean’s small molecule candidate significantly controls fibrosis progression in idiopathic pulmonary fibrosis (IPF) and Hermansky-Pudlak Syndrome (HPS) in multiple testing models. Patent granted for use in IPF, HPS, alcoholic liver disease... Full story
Yahoo Finance • last year
Ocean Biomedical’s (NASDAQ: OCEA) mRNA-based Vaccine Candidate Generates Over 90% Killing of Malaria Parasites in Non-human Primates, Demonstrating Broad Potential for Ocean’s Program to Address Global and Emerging U.S. Malaria Challenges
Multiple Patents have been received in the U.S. and Internationally for Novel Vaccine Candidate and “Whole New Class” of Malaria Therapeutics. Providence, RI, July 11, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a bi... Full story
Yahoo Finance • last year
Ocean Biomedical, Inc. Joins the Russell 2000® Index
Ocean Biomedical’s Inclusion in the Russell 2000® Index and Russell 3000® Index Builds Momentum for Cutting Edge Therapeutic Programs Targeting Multiple Cancers, Fibrotic Diseases, and Malaria Providence, RI, June 27, 2023 (GLOBE NEWSWI... Full story
Yahoo Finance • last year
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces U.S. Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells in Lung Cancer, Brain Cancer (Glioblastoma), and Metastatic Melanoma.
Patent broadens protection around Ocean Biomedical’s first-in-class anti-CHi3L1 antibody to include new bispecific approaches targeting immune checkpoints, with potential application in multiple primary, metastatic, and malignant cancers.... Full story
Yahoo Finance • last year
Ocean Biomedical (NASDAQ: OCEA) Extends Patent Rights for Breakthrough Idiopathic Pulmonary Fibrosis Discovery To Europe
Patent notice extends global coverage for breakthrough discovery, with potential for treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases, including Scleroderma, Nonalcoholic Steatohepatitis (NASH), Hermansky-Pudlak syn... Full story
Yahoo Finance • 2 years ago
Ocean Biomedical, Inc. Enters into a $25 Million Convertible Note Facility
Providence, RI, May 16, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling assets from research universities and me... Full story
Yahoo Finance • 2 years ago
Ocean Biomedical (NASDAQ: OCEA) Announces New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody
Results published in peer-reviewed Cancer Research share novel insights into Chi3L1’s role in modulating Gliomastem cells and reinforcesthe potential therapeutic impact of Anti-Chi3L1 Providence, RI, April 27, 2023 (GLOBE NEWSWIRE) -- O... Full story
